In 2022, spesolimab, a monoclonal antibody targeting the IL-36 receptor, was approved for the treatment of GPP, and the safety and efficacy of spesolimab was evaluated in a phase I trial in seven patients with moderate GPP, with all seven patients showing a 70%-80% improvement and no significant adverse events in patients or healthy controls (49). This evidence concerns the gene IL1RL2 and psoriasis 14, pustular.